BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs 2019;11:219-38. [PMID: 30516432 DOI: 10.1080/19420862.2018.1556465] [Cited by in Crossref: 338] [Cited by in F6Publishing: 280] [Article Influence: 67.6] [Reference Citation Analysis]
Number Citing Articles
1 Behl A, Wani ZA, Das NN, Parmar VS, Len C, Malhotra S, Chhillar AK. Monoclonal antibodies in breast cancer: A critical appraisal. Crit Rev Oncol Hematol 2023;183:103915. [PMID: 36702424 DOI: 10.1016/j.critrevonc.2023.103915] [Reference Citation Analysis]
2 Ambrosetti F, Jandova Z, Bonvin AMJJ. Information-Driven Antibody–Antigen Modelling with HADDOCK. Computer-Aided Antibody Design 2023. [DOI: 10.1007/978-1-0716-2609-2_14] [Reference Citation Analysis]
3 Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs 2023;15:2153410. [PMID: 36472472 DOI: 10.1080/19420862.2022.2153410] [Reference Citation Analysis]
4 Kinch MS, Kraft Z, Schwartz T. Monoclonal antibodies: Trends in therapeutic success and commercial focus. Drug Discov Today 2023;28:103415. [PMID: 36280042 DOI: 10.1016/j.drudis.2022.103415] [Reference Citation Analysis]
5 Nandal J, Mihooliya KN, Verma H, Kalidas N, Ashish F, Mishra RPN, Sahoo DK. Evaluation of physicochemical and functional similarity of a new CHO derived anti-EGFR antibody P-mAb to its reference medicinal product. Artificial Cells, Nanomedicine, and Biotechnology 2022;50:17-28. [DOI: 10.1080/21691401.2022.2028284] [Reference Citation Analysis]
6 Eidenberger L, Eminger F, Castilho A, Steinkellner H. Comparative analysis of plant transient expression vectors for targeted N-glycosylation. Front Bioeng Biotechnol 2022;10:1073455. [PMID: 36619384 DOI: 10.3389/fbioe.2022.1073455] [Reference Citation Analysis]
7 Otsubo R, Yasui T. Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin. Pharmacol Ther 2022;240:108233. [PMID: 35738431 DOI: 10.1016/j.pharmthera.2022.108233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 De Re V, Repetto O, Mussolin L, Brisotto G, Elia C, Lopci E, d'Amore ESG, Burnelli R, Mascarin M. Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma. Front Cell Dev Biol 2022;10:965803. [PMID: 36506094 DOI: 10.3389/fcell.2022.965803] [Reference Citation Analysis]
9 Castañeda Ruiz AJ, Shetab Boushehri MA, Phan T, Carle S, Garidel P, Buske J, Lamprecht A. Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates. Pharmaceutics 2022;14. [PMID: 36559072 DOI: 10.3390/pharmaceutics14122575] [Reference Citation Analysis]
10 Ausserwöger H, Schneider MM, Herling TW, Arosio P, Invernizzi G, Knowles TPJ, Lorenzen N. Non-specificity as the sticky problem in therapeutic antibody development. Nat Rev Chem 2022. [DOI: 10.1038/s41570-022-00438-x] [Reference Citation Analysis]
11 Gui T, Li H, Zhu F, Wang Q, Zhou X, Xue Q. Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials. Headache 2022;62:1281-92. [PMID: 36373822 DOI: 10.1111/head.14423] [Reference Citation Analysis]
12 Jing X, Zhu H, Li Y, Jia W, Zhai X, Li J, Yu J. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor. Immunotherapy 2022;14:1097-107. [PMID: 36093721 DOI: 10.2217/imt-2021-0215] [Reference Citation Analysis]
13 Reitinger C, Ipsen-escobedo A, Hornung C, Heger L, Dudziak D, Lux A, Nimmerjahn F. Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity. Front Immunol 2022;13:970290. [DOI: 10.3389/fimmu.2022.970290] [Reference Citation Analysis]
14 Srivastava R. Computational Studies on Antibody Drug Conjugates (ADCs) for Precision Oncology. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202202259] [Reference Citation Analysis]
15 Wang M, Wei L, Xiang H, Ren B, Liu X, Jiang L, Yang N, Shi J. A megadiverse naïve library derived from numerous camelids for efficient and rapid development of VHH antibodies. Anal Biochem 2022;657:114871. [PMID: 36108795 DOI: 10.1016/j.ab.2022.114871] [Reference Citation Analysis]
16 Salvador J, Vasylieva N, Gonzalez-garcia I, Jin M, Caster R, Siegel JB, Hammock BD. Nanobody-Based Lateral Flow Immunoassay for the Rapid Detection of Aflatoxin B1 in Almond Milk. ACS Food Sci Technol 2022;2:1276-1282. [DOI: 10.1021/acsfoodscitech.2c00118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Ihim SA, Abubakar SD, Zian Z, Sasaki T, Saffarioun M, Maleknia S, Azizi G. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment. Front Immunol 2022;13:919973. [DOI: 10.3389/fimmu.2022.919973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cohen M, Randolph DE, Lozano ME, Anderson PW, Crissman J, Triana FJ, Cujec T. A fully automated high-throughput plasmid purification workstation for the generation of mammalian cell expression-quality DNA. SLAS Technology 2022;27:227-236. [DOI: 10.1016/j.slast.2022.01.005] [Reference Citation Analysis]
19 Wang X, Song J, You C. Efficacy and Safety of Galcanezumab for Migraine: Evidences From Direct and Indirect Comparisons. Int J Neurosci 2022;:1-15. [PMID: 35815440 DOI: 10.1080/00207454.2022.2098732] [Reference Citation Analysis]
20 Gou M, Qian N, Zhang Y, Yan H, Si H, Wang Z, Dai G. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China. Front Oncol 2022;12:851756. [DOI: 10.3389/fonc.2022.851756] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Mata-molanes JJ, Rebollo-liceaga J, Martínez-navarro EM, Manzano RG, Brugarolas A, Juan M, Sureda M. Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. Front Oncol 2022;12:926289. [DOI: 10.3389/fonc.2022.926289] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Mahdavi SZB, Oroojalian F, Eyvazi S, Hejazi M, Baradaran B, Pouladi N, Tohidkia MR, Mokhtarzadeh A, Muyldermans S. An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages. Int J Biol Macromol 2022;208:421-42. [PMID: 35339499 DOI: 10.1016/j.ijbiomac.2022.03.113] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gibson K, Cooper-Shepherd DA, Pallister E, Inman SE, Jackson SE, Lindo V. Toward Rapid Aspartic Acid Isomer Localization in Therapeutic Peptides Using Cyclic Ion Mobility Mass Spectrometry. J Am Soc Mass Spectrom 2022. [PMID: 35609180 DOI: 10.1021/jasms.2c00053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Rex DAB, Vaid N, Deepak K, Dagamajalu S, Prasad TSK. A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases. Mol Biol Rep 2022. [PMID: 35596055 DOI: 10.1007/s11033-022-07539-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Gong S, Gautam S, Coneglio JD, Scinto HB, Ruprecht RM. Antibody Light Chains: Key to Increased Monoclonal Antibody Yields in Expi293 Cells? Antibodies 2022;11:37. [DOI: 10.3390/antib11020037] [Reference Citation Analysis]
26 Niu YX, Xu ZX, Yu LF, Lu YP, Wang Y, Wu C, Hou YB, Li JN, Huang S, Song X, Wang X, Wang J, Li B, Guo Y, Yu Z, Zhao L, Yi DX, Wei MJ. Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy. Int Immunopharmacol 2022;109:108783. [PMID: 35561479 DOI: 10.1016/j.intimp.2022.108783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Marino M, Holt MG. AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System. Front Neurol 2022;13:870799. [DOI: 10.3389/fneur.2022.870799] [Reference Citation Analysis]
28 Moehrle JJ. Development of New Strategies for Malaria Chemoprophylaxis: From Monoclonal Antibodies to Long-Acting Injectable Drugs. TropicalMed 2022;7:58. [DOI: 10.3390/tropicalmed7040058] [Reference Citation Analysis]
29 Dunlap T, Cao Y. Physiological Considerations for Modeling in vivo Antibody-Target Interactions. Front Pharmacol 2022;13:856961. [PMID: 35281913 DOI: 10.3389/fphar.2022.856961] [Reference Citation Analysis]
30 Ausserwöger H, Krainer G, Welsh TJ, Sneideris T, Schneider MM, Invernizzi G, Herling TW, Lorenzen N, Knowles TPJ. Surface interaction patches link non-specific binding and phase separation of antibodies.. [DOI: 10.1101/2022.03.07.483238] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Stüber JC, Rechberger KF, Miladinović SM, Pöschinger T, Zimmermann T, Villenave R, Eigenmann MJ, Kraft TE, Shah DK, Kettenberger H, Richter WF. Impact of charge patches on tumor disposition and biodistribution of therapeutic antibodies. AAPS Open 2022;8. [DOI: 10.1186/s41120-021-00048-9] [Reference Citation Analysis]
32 Henrique IDM, Sacerdoti F, Ferreira RL, Henrique C, Amaral MM, Piazza RMF, Luz D. Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives. Front Cell Infect Microbiol 2022;12:825856. [DOI: 10.3389/fcimb.2022.825856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Fernández-Quintero ML, Kroell KB, Grunewald LJ, Fischer AM, Riccabona JR, Liedl KR. CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies. MAbs 2022;14:2024118. [PMID: 35090383 DOI: 10.1080/19420862.2021.2024118] [Reference Citation Analysis]
34 Das R, Langou S, Le TT, Prasad P, Lin F, Nguyen TD. Electrical Stimulation for Immune Modulation in Cancer Treatments. Front Bioeng Biotechnol 2021;9:795300. [PMID: 35087799 DOI: 10.3389/fbioe.2021.795300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Parisi OI, Francomano F, Dattilo M, Patitucci F, Prete S, Amone F, Puoci F. The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart. JFB 2022;13:12. [DOI: 10.3390/jfb13010012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
36 Kamusheva M, Georgieva V, Marinov L, Boncheva E, Milushewa P, Grigorova P, Marinov K, Petrova G. Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective. Biotechnology & Biotechnological Equipment 2021;35:1778-91. [DOI: 10.1080/13102818.2021.2019116] [Reference Citation Analysis]
37 Gstöttner C, Haselberg R, Wuhrer M, Somsen GW, Domínguez-vega E. Assessment of Macro- and Microheterogeneity of Monoclonal Antibodies Using Capillary Zone Electrophoresis Hyphenated with Mass Spectrometry. Capillary Electrophoresis-Mass Spectrometry 2022. [DOI: 10.1007/978-1-0716-2493-7_9] [Reference Citation Analysis]
38 Schmitz S, Schmitz EA, Crowe JE Jr, Meiler J. The human antibody sequence space and structural design of the V, J regions, and CDRH3 with Rosetta. MAbs 2022;14:2068212. [PMID: 35544469 DOI: 10.1080/19420862.2022.2068212] [Reference Citation Analysis]
39 Garzone PD, Wang YC. Pharmacokinetic and pharmacodynamic considerations in the development of biotechnology products and large molecules. Atkinson's Principles of Clinical Pharmacology 2022. [DOI: 10.1016/b978-0-12-819869-8.00011-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Fraguas-sanchez A, Martin-sabroso C, Fernandez-carballido A, Torres-suarez A. Current status of nanomedicine for breast cancer treatment. Targeted Nanomedicine for Breast Cancer Therapy 2022. [DOI: 10.1016/b978-0-12-824476-0.00014-0] [Reference Citation Analysis]
41 Rubin SJ, Qvit N. Preface. Peptide and Peptidomimetic Therapeutics 2022. [DOI: 10.1016/b978-0-12-820141-1.00024-8] [Reference Citation Analysis]
42 de Lima Fontes M, Neves FML, Santos KS, Fusco-Almeida AM, Giannini MJSM, Felisbino SL, Deffune E, Moroz A. Multiple Tolerization Subtractive Immunization (MTSI) Protocol: Effects on Mice and Monoclonal Antibody Specificity. Front Immunol 2021;12:760817. [PMID: 34950138 DOI: 10.3389/fimmu.2021.760817] [Reference Citation Analysis]
43 Westlund KN, Montera MA, Goins AE, Alles SRA, Suri N, McIlwrath SL, Bartel R, Durvasula RV, Kunamneni A. Single-Dose P2 X4R Single-Chain Fragment Variable Antibody Permanently Reverses Chronic Pain in Male Mice. Int J Mol Sci 2021;22:13612. [PMID: 34948407 DOI: 10.3390/ijms222413612] [Reference Citation Analysis]
44 Jafarpour R, Pashangzadeh S, Dowran R. Host factors: Implications in immunopathogenesis of COVID-19. Pathol Res Pract 2021;228:153647. [PMID: 34749207 DOI: 10.1016/j.prp.2021.153647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Srdic-Rajic T, Metlas R. Antibody VH domain sequence analysis by a bioinformatics approach based on electronic amino acid properties may help to predict paratop location. Immunol Lett 2021:S0165-2478(21)00172-3. [PMID: 34785254 DOI: 10.1016/j.imlet.2021.11.003] [Reference Citation Analysis]
46 Isozaki Y, Tsumoto K, Tomita M. Class-Switching of B Lymphocytes by DNA and Cell Immunization for Stereospecific Monoclonal Antibodies against Native GPCR. Immuno 2021;1:432-41. [DOI: 10.3390/immuno1040031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Broster Reix CE, Ramanantsalama MR, Di Primo C, Minder L, Bonhivers M, Dacheux D, Robinson DR. Intrabody-Induced Cell Death by Targeting the T. brucei Cytoskeletal Protein TbBILBO1. Microbiol Spectr 2021;9:e0091521. [PMID: 34704826 DOI: 10.1128/Spectrum.00915-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Bléry M, Mrabet-kraiem M, Morel A, Lhospice F, Bregeon D, Bonnafous C, Gauthier L, Rossi B, Remark R, Cornen S, Anceriz N, Viaud N, Trichard S, Carpentier S, Joulin-giet A, Grondin G, Liptakova V, Kim Y, Daniel L, Haffner A, Macagno N, Pouyet L, Perrot I, Paturel C, Morel Y, Steinle A, Romagné F, Narni-mancinelli E, Vivier E. Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. Open Res Europe 2021;1:107. [DOI: 10.12688/openreseurope.13314.2] [Reference Citation Analysis]
49 Cruz E, Sifniotis V, Sumer-Bayraktar Z, Reslan M, Wilkinson-White L, Cordwell S, Kayser V. Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity. Pharmaceutics 2021;13:1747. [PMID: 34834161 DOI: 10.3390/pharmaceutics13111747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol 2021;19:159. [PMID: 34661773 DOI: 10.1186/s43141-021-00264-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
51 Mota LM, Tayi VS, Butler M. Cell Free Remodeling of Glycosylation of Antibodies. Methods Mol Biol 2022;2370:117-46. [PMID: 34611867 DOI: 10.1007/978-1-0716-1685-7_6] [Reference Citation Analysis]
52 Chen G, Tao L, Li Z. Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics. Drug Discov Today 2022;27:196-206. [PMID: 34571276 DOI: 10.1016/j.drudis.2021.09.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
53 Gan HK, Parakh S, Lassman AB, Seow A, Lau E, Lee ST, Ameratunga M, Perchyonok Y, Cao D, Burvenich IJG, O'Keefe GJ, Rigopoulos A, Gomez E, Maag D, Scott AM. Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. Neurooncol Adv 2021;3:vdab102. [PMID: 34549181 DOI: 10.1093/noajnl/vdab102] [Reference Citation Analysis]
54 Kulagina N, Besseau S, Godon C, Goldman GH, Papon N, Courdavault V. Yeasts as Biopharmaceutical Production Platforms. Front Fungal Biol 2021;2:733492. [DOI: 10.3389/ffunb.2021.733492] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
55 Bléry M, Mrabet-kraiem M, Morel A, Lhospice F, Bregeon D, Bonnafous C, Gauthier L, Rossi B, Remark R, Cornen S, Anceriz N, Viaud N, Trichard S, Carpentier S, Joulin-giet A, Grondin G, Liptakova V, Kim Y, Daniel L, Haffner A, Macagno N, Pouyet L, Perrot I, Paturel C, Morel Y, Steinle A, Romagné F, Narni-mancinelli E, Vivier E. Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. Open Res Europe 2021;1:107. [DOI: 10.12688/openreseurope.13314.1] [Reference Citation Analysis]
56 Shan L, Dyk NV, Haskins N, Cook KM, Rosenthal KL, Mazor R, Dragulin-Otto S, Jiang Y, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Oganesyan V. In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance. Commun Biol 2021;4:1048. [PMID: 34497355 DOI: 10.1038/s42003-021-02565-5] [Reference Citation Analysis]
57 Fazekas-Singer J, Singer J, Jensen-Jarolim E. Precision medicine in clinical oncology: the journey from IgG antibody to IgE. Curr Opin Allergy Clin Immunol 2020;20:282-9. [PMID: 32349107 DOI: 10.1097/ACI.0000000000000637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Chen H, Chen J, Paerhati P, Jakos T, Bai S, Zhu J, Yuan Y. Strategies and Applications of Antigen-Binding Fragment (Fab) Production in Escherichia coli. Pharmaceutical Fronts 2021;03:e39-49. [DOI: 10.1055/s-0041-1735145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Kole C, Charalampakis N, Vailas M, Tolia M, Sotiropoulou M, Tsakatikas S, Kouris NI, Tsoli M, Koumarianou A, Karamouzis MV, Schizas D. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update. Cancer Immunol Immunother 2021. [PMID: 34471940 DOI: 10.1007/s00262-021-03046-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Han N, Oh JM, Kim IW. Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems. Ther Clin Risk Manag 2021;17:877-87. [PMID: 34456568 DOI: 10.2147/TCRM.S321789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Ghazawi FM, Mahmood F, Kircik L, Poulin Y, Bourcier M, Vender R, Wiseman MC, Lynde C, Litvinov IV. A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Front Med (Lausanne) 2021;8:702776. [PMID: 34447766 DOI: 10.3389/fmed.2021.702776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
62 Li F, Wang Y, Xie K, Fang Y, Du Y, Hou L, Tan W. The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. Aging (Albany NY) 2021;13:20468-80. [PMID: 34424218 DOI: 10.18632/aging.203429] [Reference Citation Analysis]
63 Shabani S, Moghadam MF, Gargari SLM. Isolation and characterization of a novel GRP78-specific single-chain variable fragment (scFv) using ribosome display method. Med Oncol 2021;38:115. [PMID: 34390413 DOI: 10.1007/s12032-021-01561-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Tan Z, Ehamparanathan V, Ren T, Tang P, Hoffman L, Kuang J, Liu P, Huang C, Du C, Tao L, Chemmalil L, Lewandowski A, Ghose S, Li ZJ, Liu S. On-column disulfide bond formation of monoclonal antibodies during Protein A chromatography eliminates low molecular weight species and rescues reduced antibodies. MAbs 2020;12:1829333. [PMID: 33016217 DOI: 10.1080/19420862.2020.1829333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Valente D, Mauriac C, Schmidt T, Focken I, Beninga J, Mackness B, Qiu H, Vicat P, Kandira A, Radošević K, Rao S, Darbyshire J, Kabiri M. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models. mAbs 2020;12:1829337. [DOI: 10.1080/19420862.2020.1829337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Kandari D, Bhatnagar R. Antibody engineering and its therapeutic applications. Int Rev Immunol 2021;:1-28. [PMID: 34355613 DOI: 10.1080/08830185.2021.1960986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Li C, Chi H, Deng S, Wang H, Yao H, Wang Y, Chen D, Guo X, Fang JY, He F, Xu J. THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. J Immunother Cancer 2021;9:e002443. [PMID: 34341130 DOI: 10.1136/jitc-2021-002443] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Saleh D, Wang G, Rischawy F, Kluters S, Studts J, Hubbuch J. In silico process characterization for biopharmaceutical development following the quality by design concept. Biotechnol Prog 2021;:e3196. [PMID: 34309240 DOI: 10.1002/btpr.3196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
69 Sokka IK, Imlimthan S, Sarparanta M, Maaheimo H, Johansson MP, Ekholm FS. Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity. Mol Pharm 2021;18:3125-31. [PMID: 34296616 DOI: 10.1021/acs.molpharmaceut.1c00342] [Reference Citation Analysis]
70 Walsh SJ, Iegre J, Seki H, Bargh JD, Sore HF, Parker JS, Carroll JS, Spring DR. General dual functionalisation of biomacromolecules via a cysteine bridging strategy. Org Biomol Chem 2020;18:4224-30. [PMID: 32432632 DOI: 10.1039/d0ob00907e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
71 Broster Reix CE, Ramanantsalama MR, Primo CD, Minder L, Bonhivers M, Dacheux D, Robinson DR. Intrabody induced cell death by targeting the T. brucei cytoskeletal protein TbBILBO1.. [DOI: 10.1101/2021.07.18.452872] [Reference Citation Analysis]
72 Eaton M, Que Z, Zhang J, Beck K, Shi R, McDermott J, Ladisch M, Yang Y. Multi-Electrode Array of Sensory Neurons as an In Vitro Platform to Identify the Nociceptive Response to Pharmaceutical Buffer Systems of Injectable Biologics. Pharm Res 2021;38:1179-86. [PMID: 34244893 DOI: 10.1007/s11095-021-03075-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Li M, Yu C, Wang W, Wu G, Wang L. Interlaboratory method validation of capillary electrophoresis sodium dodecyl sulfate (CE-SDS) methodology for analysis of mAbs. Electrophoresis 2021. [PMID: 34240427 DOI: 10.1002/elps.202000396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
74 Cure E, Kucuk A, Cure MC. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors. Indian J Pharmacol 2021;53:226-8. [PMID: 34169908 DOI: 10.4103/ijp.IJP_615_20] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
75 Handlogten MW, Peng L, Christian EA, Xu W, Lin S, Venkat R, Dall'Acqua W, Ahuja S. Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region. MAbs 2020;12:1779974. [PMID: 32633193 DOI: 10.1080/19420862.2020.1779974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
76 Pekar L, Busch M, Valldorf B, Hinz SC, Toleikis L, Krah S, Zielonka S. Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform. MAbs 2020;12:1812210. [PMID: 32887531 DOI: 10.1080/19420862.2020.1812210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
77 Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A. Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. MAbs 2020;12:1792084. [PMID: 32643525 DOI: 10.1080/19420862.2020.1792084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
78 Phumrattanaprapin W, Pearson M, Pickering D, Tedla B, Smout M, Chaiyadet S, Brindley PJ, Loukas A, Laha T. Monoclonal Antibodies Targeting an Opisthorchis viverrini Extracellular Vesicle Tetraspanin Protect Hamsters against Challenge Infection. Vaccines (Basel) 2021;9:740. [PMID: 34358156 DOI: 10.3390/vaccines9070740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Cure E, Kucuk A, Cure MC. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors. Indian J Pharmacol 2021;53:226-8. [PMID: 34169908 DOI: 10.4103/ijp.IJP_615_20] [Reference Citation Analysis]
80 Swope K, Morton J, Pogue GP, Hume S, Pauly MH, Shepherd J, Simpson CA, Bratcher B, Whaley KJ, Zeitlin L, Davis KR, Haydon H. Manufacturing plant-made monoclonal antibodies for research or therapeutic applications. Methods Enzymol 2021;660:239-63. [PMID: 34742392 DOI: 10.1016/bs.mie.2021.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kast F, Schwill M, Stüber JC, Pfundstein S, Nagy-Davidescu G, Rodríguez JMM, Seehusen F, Richter CP, Honegger A, Hartmann KP, Weber TG, Kroener F, Ernst P, Piehler J, Plückthun A. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. Nat Commun 2021;12:3790. [PMID: 34145240 DOI: 10.1038/s41467-021-23948-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
82 Ling P, Zheng X, Luo S, Ge J, Xu S, Weng J. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside. Diabetes Obes Metab 2021;23:2020-34. [PMID: 34047441 DOI: 10.1111/dom.14450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
83 Ferreira JA, Relvas-Santos M, Peixoto A, M N Silva A, Lara Santos L. Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. Genomics Proteomics Bioinformatics 2021:S1672-0229(21)00097-8. [PMID: 34118464 DOI: 10.1016/j.gpb.2021.03.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
84 Atsumi Y, Sakurai N, Nishimura K, Yamazaki K, Wakamatsu K. Identification and Characterization of a Monoclonal Antibody Variant Species with a Clipping in the Complementarity Determining Region Isolated by Size Exclusion Chromatography Under Native Conditions. J Pharm Sci 2021:S0022-3549(21)00288-4. [PMID: 34089708 DOI: 10.1016/j.xphs.2021.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Spuntarelli V, Negro A, Luciani M, Bentivegna E, Martelletti P. Eptinezumab for the treatment of migraine. Expert Opin Biol Ther 2021;21:999-1011. [PMID: 34009094 DOI: 10.1080/14712598.2021.1931678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
86 Saleh D, Hess R, Ahlers-Hesse M, Beckert N, Schönberger M, Rischawy F, Wang G, Bauer J, Blech M, Kluters S, Studts J, Hubbuch J. Modeling the impact of amino acid substitution in a monoclonal antibody on cation exchange chromatography. Biotechnol Bioeng 2021;118:2923-33. [PMID: 33871060 DOI: 10.1002/bit.27798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Fernández-Quintero ML, Georges G, Varga JM, Liedl KR. Ensembles in solution as a new paradigm for antibody structure prediction and design. MAbs 2021;13:1923122. [PMID: 34030577 DOI: 10.1080/19420862.2021.1923122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
88 Scott MJ, Jowett A, Orecchia M, Ertl P, Ouro-Gnao L, Ticehurst J, Gower D, Yates J, Poulton K, Harris C, Mullin MJ, Smith KJ, Lewis AP, Barton N, Washburn ML, de Wildt R. Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies. MAbs 2020;12:1755069. [PMID: 32343620 DOI: 10.1080/19420862.2020.1755069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Farid SS, Baron M, Stamatis C, Nie W, Coffman J. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. MAbs 2020;12:1754999. [PMID: 32449439 DOI: 10.1080/19420862.2020.1754999] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
90 Kostova V, Désos P, Starck JB, Kotschy A. The Chemistry Behind ADCs. Pharmaceuticals (Basel) 2021;14:442. [PMID: 34067144 DOI: 10.3390/ph14050442] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
91 Shi X, Wan Y, Wang N, Xiang J, Wang T, Yang X, Wang J, Dong X, Dong L, Yan L, Li Y, Liu L, Hou S, Zhong Z, Wilson IA, Yang B, Yang G, Lerner RA. Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms. Nat Commun 2021;12:2547. [PMID: 33953162 DOI: 10.1038/s41467-021-22810-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
92 Motabar D, Li J, Wang S, Tsao CY, Tong X, Wang LX, Payne GF, Bentley WE. Simple, rapidly electroassembled thiolated PEG-based sensor interfaces enable rapid interrogation of antibody titer and glycosylation. Biotechnol Bioeng 2021;118:2744-58. [PMID: 33851726 DOI: 10.1002/bit.27793] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Allmendinger A. Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products. Pharm Res 2021;38:739-57. [PMID: 33903976 DOI: 10.1007/s11095-021-03037-5] [Reference Citation Analysis]
94 Brady JR, Love JC. Alternative hosts as the missing link for equitable therapeutic protein production. Nat Biotechnol 2021;39:404-7. [PMID: 33782611 DOI: 10.1038/s41587-021-00884-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
95 Shi C, Vogg S, Lin DQ, Sponchioni M, Morbidelli M. Analysis and optimal design of batch and two-column continuous chromatographic frontal processes for monoclonal antibody purification. Biotechnol Bioeng 2021;118:3420-34. [PMID: 33755192 DOI: 10.1002/bit.27763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
96 Grisafi D, Ceschi A, Avalos Clerici V, Scaglione F. The Contribution of Clinical Pharmacologists in Precision Medicine: An Opportunity for Health Care Improvement. Curr Ther Res Clin Exp 2021;94:100628. [PMID: 34306268 DOI: 10.1016/j.curtheres.2021.100628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
97 Golpour M, Vatanpour P, Amini M, Saeedi M, Hafezi N, Rafiei A. The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025. Adv Pharmacol Pharm Sci 2021;2021:5569590. [PMID: 33860229 DOI: 10.1155/2021/5569590] [Reference Citation Analysis]
98 Tanaka Y, Murata M, Oda Y, Furue M, Ito T. Nectin Cell Adhesion Molecule 4 (NECTIN4) Expression in Cutaneous Squamous Cell Carcinoma: A New Therapeutic Target? Biomedicines 2021;9:355. [PMID: 33808400 DOI: 10.3390/biomedicines9040355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
99 Jyothilekshmi I, Jayaprakash NS. Trends in Monoclonal Antibody Production Using Various Bioreactor Syst. J Microbiol Biotechnol 2021;31:349-57. [PMID: 32238761 DOI: 10.4014/jmb.1911.11066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
100 Haberger M, Heidenreich AK, Hook M, Fichtl J, Lang R, Cymer F, Adibzadeh M, Kuhne F, Wegele H, Reusch D, Bonnington L, Bulau P. Multiattribute Monitoring of Antibody Charge Variants by Cation-Exchange Chromatography Coupled to Native Mass Spectrometry. J Am Soc Mass Spectrom 2021;32:2062-71. [PMID: 33687195 DOI: 10.1021/jasms.0c00446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
101 Ambrosetti F, Olsen TH, Olimpieri PP, Jiménez-García B, Milanetti E, Marcatilli P, Bonvin AMJJ. proABC-2: PRediction of AntiBody contacts v2 and its application to information-driven docking. Bioinformatics 2020;36:5107-8. [PMID: 32683441 DOI: 10.1093/bioinformatics/btaa644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
102 Thouvenel CD, Fontana MF, Netland J, Krishnamurty AT, Takehara KK, Chen Y, Singh S, Miura K, Keitany GJ, Lynch EM, Portugal S, Miranda MC, King NP, Kollman JM, Crompton PD, Long CA, Pancera M, Rawlings DJ, Pepper M. Multimeric antibodies from antigen-specific human IgM+ memory B cells restrict Plasmodium parasites. J Exp Med 2021;218:e20200942. [PMID: 33661302 DOI: 10.1084/jem.20200942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
103 Fernández-Quintero ML, Kroell KB, Hofer F, Riccabona JR, Liedl KR. Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution. Front Immunol 2021;12:630034. [PMID: 33737932 DOI: 10.3389/fimmu.2021.630034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
104 Jiang CT, Chen KG, Liu A, Huang H, Fan YN, Zhao DK, Ye QN, Zhang HB, Xu CF, Shen S, Xiong MH, Du JZ, Yang XZ, Wang J. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy. Nat Commun 2021;12:1359. [PMID: 33649336 DOI: 10.1038/s41467-021-21497-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
105 Song YE, Dubois H, Hoffmann M, D́eri S, Fromentin Y, Wiesner J, Pfenninger A, Clavier S, Pieper A, Duhau L, Roth U. Automated mass spectrometry multi-attribute method analyses for process development and characterization of mAbs. Journal of Chromatography B 2021;1166:122540. [DOI: 10.1016/j.jchromb.2021.122540] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
106 Piramoon M, Khodadust F, Hosseinimehr SJ. Radiolabeled nanobodies for tumor targeting: From bioengineering to imaging and therapy. Biochim Biophys Acta Rev Cancer 2021;1875:188529. [PMID: 33647388 DOI: 10.1016/j.bbcan.2021.188529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Rincon Pabon JP, Kochert BA, Liu YH, Richardson DD, Weis DD. Protein A does not induce allosteric structural changes in an IgG1 antibody during binding. J Pharm Sci 2021;110:2355-61. [PMID: 33640336 DOI: 10.1016/j.xphs.2021.02.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
108 Lu Z, Truex NL, Melo MB, Cheng Y, Li N, Irvine DJ, Pentelute BL. IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells. ACS Cent Sci 2021;7:365-78. [PMID: 33655074 DOI: 10.1021/acscentsci.0c01670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Soliman C, Guy AJ, Chua JX, Vankemmelbeke M, McIntosh RS, Eastwood S, Truong VK, Elbourne A, Spendlove I, Durrant LG, Ramsland PA. Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody. Biochem J 2020;477:3219-35. [PMID: 32789497 DOI: 10.1042/BCJ20200454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
110 Mieczkowski C, Cheng A, Fischmann T, Hsieh M, Baker J, Uchida M, Raghunathan G, Strickland C, Fayadat-Dilman L. Characterization and Modeling of Reversible Antibody Self-Association Provide Insights into Behavior, Prediction, and Correction. Antibodies (Basel) 2021;10:8. [PMID: 33671864 DOI: 10.3390/antib10010008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Lawrence SA, Blankenship R, Brown R, Estwick S, Ellis B, Thangaraju A, Datta-Mannan A. Influence of FcRn binding properties on the gastrointestinal absorption and exposure profile of Fc molecules. Bioorg Med Chem 2021;32:115942. [PMID: 33461147 DOI: 10.1016/j.bmc.2020.115942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
112 Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, Yu Y, Park J, Raghava S, Welsh J, Rauscher M, Raghunathan G, Hsieh M, Chen YL, Nguyen HT, Nguyen N, Cipriano D, Fayadat-Dilman L. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening. MAbs 2020;12:1743053. [PMID: 32249670 DOI: 10.1080/19420862.2020.1743053] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 25.5] [Reference Citation Analysis]
113 Fernández-Quintero ML, Heiss MC, Pomarici ND, Math BA, Liedl KR. Antibody CDR loops as ensembles in solution vs. canonical clusters from X-ray structures. MAbs 2020;12:1744328. [PMID: 32264741 DOI: 10.1080/19420862.2020.1744328] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
114 De Santis R. Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. MAbs 2020;12:1725346. [PMID: 32054397 DOI: 10.1080/19420862.2020.1725346] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
115 Hatterer E, Chauchet X, Richard F, Barba L, Moine V, Chatel L, Broyer L, Pontini G, Bautzova T, Juan F, Calloud S, Bosson N, Charreton M, Masternak K, Buatois V, Shang L. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. MAbs 2020;12:1739408. [PMID: 32191151 DOI: 10.1080/19420862.2020.1739408] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
116 Qi H, Ma M, Hu C, Xu ZW, Wu FL, Wang N, Lai DY, Li Y, Zhang H, Jiang HW, Meng QF, Guo S, Kang Y, Zhao X, Li H, Tao SC. Antibody Binding Epitope Mapping (AbMap) of Hundred Antibodies in a Single Run. Mol Cell Proteomics 2021;20:100059. [PMID: 33109704 DOI: 10.1074/mcp.RA120.002314] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
117 Shen X, Liang Z, Xu T, Yang Z, Wang Q, Chen D, Pham L, Du W, Sun L. Investigating native capillary zone electrophoresis-mass spectrometry on a high-end quadrupole-time-of-flight mass spectrometer for the characterization of monoclonal antibodies. Int J Mass Spectrom 2021;462:116541. [PMID: 33642939 DOI: 10.1016/j.ijms.2021.116541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
118 Hao D, Zhang R, Ge J, Ye P, Song C, Zhu K, Na X, Huang Y, Zhao L, Zhou W, Su Z, Ma G. Rapid and high-capacity loading of IgG monoclonal antibodies by polymer brush and peptides functionalized microspheres. J Chromatogr A 2021;1640:461948. [PMID: 33561708 DOI: 10.1016/j.chroma.2021.461948] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
119 Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs 2021;13:1860476. [PMID: 33459118 DOI: 10.1080/19420862.2020.1860476] [Cited by in Crossref: 156] [Cited by in F6Publishing: 124] [Article Influence: 78.0] [Reference Citation Analysis]
120 Dondapati SK, Stech M, Zemella A, Kubick S. Cell-Free Protein Synthesis: A Promising Option for Future Drug Development. BioDrugs 2020;34:327-48. [PMID: 32198631 DOI: 10.1007/s40259-020-00417-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
121 Arslan FB, Ozturk Atar K, Calis S. Antibody-mediated drug delivery. Int J Pharm 2021;596:120268. [PMID: 33486037 DOI: 10.1016/j.ijpharm.2021.120268] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
122 Tanaka Y, Murata M, Shen CH, Furue M, Ito T. NECTIN4: A Novel Therapeutic Target for Melanoma. Int J Mol Sci 2021;22:976. [PMID: 33478111 DOI: 10.3390/ijms22020976] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
123 Hu S, Xiong H, Kang X, Wang S, Zhang T, Yuan Q, Tian D. Preparation and functional evaluation of monoclonal antibodies targeting Hepatitis B Virus Polymerase. Virulence 2021;12:188-94. [PMID: 33356842 DOI: 10.1080/21505594.2020.1869391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Root AR, Guntas G, Katragadda M, Apgar JR, Narula J, Chang CS, Hanscom S, McKenna M, Wade J, Meade C, Ma W, Guo Y, Liu Y, Duan W, Hendershot C, King AC, Zhang Y, Sousa E, Tam A, Benard S, Yang H, Kelleher K, Jin F, Piche-Nicholas N, Keating SE, Narciandi F, Lawrence-Henderson R, Arai M, Stochaj WR, Svenson K, Mosyak L, Lam K, Francis C, Marquette K, Wroblewska L, Zhu HL, Sheehan AD, LaVallie ER, D'Antona AM, Betts A, King L, Rosfjord E, Cunningham O, Lin L, Sapra P, Tchistiakova L, Mathur D, Bloom L. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs 2021;13:1850395. [PMID: 33459147 DOI: 10.1080/19420862.2020.1850395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Ibaraki H, Takeda A, Arima N, Hatakeyama N, Takashima Y, Seta Y, Kanazawa T. In Vivo Fluorescence Imaging of Passive Inflammation Site Accumulation of Liposomes via Intravenous Administration Focused on Their Surface Charge and PEG Modification. Pharmaceutics 2021;13:104. [PMID: 33466905 DOI: 10.3390/pharmaceutics13010104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
126 Dunn ZD, Desai J, Leme GM, Stoll DR, Richardson DD. Rapid two-dimensional Protein-A size exclusion chromatography of monoclonal antibodies for titer and aggregation measurements from harvested cell culture fluid samples. MAbs 2020;12:1702263. [PMID: 31876441 DOI: 10.1080/19420862.2019.1702263] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
127 Jones J, Pack L, Hunter JH, Valliere-Douglass JF. Native size-exclusion chromatography-mass spectrometry: suitability for antibody-drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels. MAbs 2020;12:1682895. [PMID: 31769727 DOI: 10.1080/19420862.2019.1682895] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
128 Ferrara F, Teixeira AA, Naranjo L, Erasmus MF, D'Angelo S, Bradbury ARM. Exploiting next-generation sequencing in antibody selections - a simple PCR method to recover binders. MAbs 2020;12:1701792. [PMID: 31829073 DOI: 10.1080/19420862.2019.1701792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs 2020;12:1703531. [PMID: 31847708 DOI: 10.1080/19420862.2019.1703531] [Cited by in Crossref: 290] [Cited by in F6Publishing: 239] [Article Influence: 145.0] [Reference Citation Analysis]
130 Hoover JM, Prinslow EG, Teigler JE, Truppo MD, La Porte SL. Therapeutic antibody discovery. Remington 2021. [DOI: 10.1016/b978-0-12-820007-0.00023-4] [Reference Citation Analysis]
131 Kozani PS, Kozani PS, O'Connor RS. Humanized Chimeric Antigen Receptor (CAR) T cells. J Cancer Immunol (Wilmington) 2021;3:183-7. [PMID: 35128536] [Reference Citation Analysis]
132 Klemm J, Pekar L, Krah S, Zielonka S. Antibody Display Systems. Learning Materials in Biosciences 2021. [DOI: 10.1007/978-3-030-54630-4_4] [Reference Citation Analysis]
133 Meyer DW, Li F, Lyon RP. Contribution of Nontarget Cells to the Disposition, Antitumor Activity, and Antigen-Independent Toxicity of Antibody–Drug Conjugates. Methods in Pharmacology and Toxicology 2021. [DOI: 10.1007/978-1-0716-1250-7_16] [Reference Citation Analysis]
134 Kumar C, Singh RP, Dwiwedi MK, Amit A. Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential. Colon Cancer Diagnosis and Therapy 2021. [DOI: 10.1007/978-3-030-63369-1_14] [Reference Citation Analysis]
135 Baldo BA, Pham NH. Biologics: Monoclonal Antibodies for Non-cancer Therapy, Cytokines, Fusion Proteins, Enzymes, and Hormones. Drug Allergy 2021. [DOI: 10.1007/978-3-030-51740-3_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Wozniak-knopp G. Bispecific Antibodies. Learning Materials in Biosciences 2021. [DOI: 10.1007/978-3-030-54630-4_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Guin D, Thakran S, Singh P, Ramachandran S, Hasija Y, Kukreti R. Translational biotechnology: A transition from basic biology to evidence-based research. Translational Biotechnology 2021. [DOI: 10.1016/b978-0-12-821972-0.00006-x] [Reference Citation Analysis]
138 Saini S, Kumar Y. Bispecific antibodies: A promising entrant in cancer immunotherapy. Translational Biotechnology 2021. [DOI: 10.1016/b978-0-12-821972-0.00014-9] [Reference Citation Analysis]
139 Baldo BA, Pham NH. Targeted Drugs for Cancer Therapy: Small Molecules and Monoclonal Antibodies. Drug Allergy 2021. [DOI: 10.1007/978-3-030-51740-3_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Morishita R, Takahashi H, Sawasaki T. Cell-Free Based Protein Array Technology. Springer Proceedings in Mathematics & Statistics 2021. [DOI: 10.1007/978-981-16-4866-3_18] [Reference Citation Analysis]
141 Geist B, Zheng S, Xu Y. Therapeutic antibody development—Remington chapter. Remington 2021. [DOI: 10.1016/b978-0-12-820007-0.00024-6] [Reference Citation Analysis]
142 Cruz E, Kayser V. Major Classes of Biotherapeutics. Biologics, Biosimilars, and Biobetters 2020. [DOI: 10.1002/9781119564690.ch4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Scheffel J, Hober S. Highly selective Protein A resin allows for mild sodium chloride-mediated elution of antibodies. J Chromatogr A 2021;1637:461843. [PMID: 33412291 DOI: 10.1016/j.chroma.2020.461843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
144 Li C, Yao H, Wang H, Fang JY, Xu J. Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity. Oncogene 2021;40:1128-46. [PMID: 33323966 DOI: 10.1038/s41388-020-01592-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
145 Hutchings CJ. Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels. Antib Ther 2020;3:257-64. [PMID: 33912796 DOI: 10.1093/abt/tbaa023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Sjögren J, Lood R, Nägeli A. On enzymatic remodeling of IgG glycosylation; unique tools with broad applications. Glycobiology 2020;30:254-67. [PMID: 31616919 DOI: 10.1093/glycob/cwz085] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
147 Valanti EK, Dalakoura-Karagkouni K, Siasos G, Kardassis D, Eliopoulos AG, Sanoudou D. Advances in biological therapies for dyslipidemias and atherosclerosis. Metabolism 2021;116:154461. [PMID: 33290761 DOI: 10.1016/j.metabol.2020.154461] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
148 van Dongen GAMS, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, van Kuijk C, Boellaard R, Huisman MC, Vugts DJ. The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. J Nucl Med 2021;62:438-45. [PMID: 33277395 DOI: 10.2967/jnumed.119.239558] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
149 Zhang H, Dalby PA. Stability enhancement in a mAb and Fab coformulation. Sci Rep 2020;10:21129. [PMID: 33273491 DOI: 10.1038/s41598-020-77989-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 Wang Y, Lü W, Dai R, Lin B, Lv R. Lanthanide-semiconductor probes for precise imaging-guided phototherapy and immunotherapy. Journal of Bio-X Research 2020;3:193-204. [DOI: 10.1097/jbr.0000000000000083] [Reference Citation Analysis]
151 Goyon A, Mcdonald D, Fekete S, Guillarme D, Stella C. Development of an innovative salt-mediated pH gradient cation exchange chromatography method for the characterization of therapeutic antibodies. Journal of Chromatography B 2020;1160:122379. [DOI: 10.1016/j.jchromb.2020.122379] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
152 Gao Z, Zhang Q, Shi C, Gou J, Gao D, Wang H, Yao S, Lin D. Antibody capture with twin-column continuous chromatography: Effects of residence time, protein concentration and resin. Separation and Purification Technology 2020;253:117554. [DOI: 10.1016/j.seppur.2020.117554] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
153 Fernández-Quintero ML, Kroell KB, Heiss MC, Loeffler JR, Quoika PK, Waibl F, Bujotzek A, Moessner E, Georges G, Liedl KR. Surprisingly Fast Interface and Elbow Angle Dynamics of Antigen-Binding Fragments. Front Mol Biosci 2020;7:609088. [PMID: 33330636 DOI: 10.3389/fmolb.2020.609088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
154 Rouhimoghadam M, Lu AS, Salem AK, Filardo EJ. Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function. Front Endocrinol (Lausanne) 2020;11:591217. [PMID: 33329395 DOI: 10.3389/fendo.2020.591217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
155 Waibl F, Fernández-Quintero ML, Kamenik AS, Kraml J, Hofer F, Kettenberger H, Georges G, Liedl KR. Conformational Ensembles of Antibodies Determine Their Hydrophobicity. Biophys J 2021;120:143-57. [PMID: 33220303 DOI: 10.1016/j.bpj.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
156 Kurumida Y, Saito Y, Kameda T. Predicting antibody affinity changes upon mutations by combining multiple predictors. Sci Rep 2020;10:19533. [PMID: 33177627 DOI: 10.1038/s41598-020-76369-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
157 Shimizu Y, Shinoda T, Shirasago Y, Kondoh M, Shinya N, Hanada K, Yagi K, Suzuki T, Wakita T, Kimura-Someya T, Shirouzu M, Fukasawa M. Occludin-binding single-chain variable fragment and antigen-binding fragment antibodies prevent hepatitis C virus infection. FEBS Lett 2021;595:220-9. [PMID: 33113151 DOI: 10.1002/1873-3468.13975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
158 Crissman J, Lin Y, Separa K, Duquette M, Cohen M, Velasquez C, Cujec T. RNase H-dependent PCR enables highly specific amplification of antibody variable domains from single B-cells. PLoS One 2020;15:e0241803. [PMID: 33152031 DOI: 10.1371/journal.pone.0241803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
159 Nadal L, Corbellari R, Villa A, Weiss T, Weller M, Neri D, De Luca R. Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo. MAbs 2020;12:1836713. [PMID: 33136526 DOI: 10.1080/19420862.2020.1836713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
160 Kim NA, Hada S, Jeong SH. N-Acetylated-L-arginine (NALA) is an enhanced protein aggregation suppressor under interfacial stresses and elevated temperature for protein liquid formulations. Int J Biol Macromol 2021;166:654-64. [PMID: 33137385 DOI: 10.1016/j.ijbiomac.2020.10.223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
161 McMahon JT, Faraj RR, Adamson DC. Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. Expert Opin Investig Drugs 2020;29:1389-406. [PMID: 33040640 DOI: 10.1080/13543784.2020.1836154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 Ladel S, Maigler F, Flamm J, Schlossbauer P, Handl A, Hermann R, Herzog H, Hummel T, Mizaikoff B, Schindowski K. Impact of Glycosylation and Species Origin on the Uptake and Permeation of IgGs through the Nasal Airway Mucosa. Pharmaceutics 2020;12:E1014. [PMID: 33114132 DOI: 10.3390/pharmaceutics12111014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
163 Ibeanu N, Egbu R, Onyekuru L, Javaheri H, Khaw PT, Williams GR, Brocchini S, Awwad S. Injectables and Depots to Prolong Drug Action of Proteins and Peptides. Pharmaceutics 2020;12:E999. [PMID: 33096803 DOI: 10.3390/pharmaceutics12100999] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
164 Liu SY, Wu YL. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs 2020;29:1355-64. [PMID: 33044117 DOI: 10.1080/13543784.2020.1833857] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
165 Fernández-Quintero ML, Pomarici ND, Math BA, Kroell KB, Waibl F, Bujotzek A, Georges G, Liedl KR. Antibodies exhibit multiple paratope states influencing VH-VL domain orientations. Commun Biol 2020;3:589. [PMID: 33082531 DOI: 10.1038/s42003-020-01319-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
166 Bousbaine D, Ploegh HL. Antigen discovery tools for adaptive immune receptor repertoire research. Curr Opin Syst Biol 2020;24:64-70. [PMID: 33195881 DOI: 10.1016/j.coisb.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Natarajan A. Copper-64-immunoPET imaging: bench to bedside. Q J Nucl Med Mol Imaging 2020;64:356-63. [PMID: 33045821 DOI: 10.23736/S1824-4785.20.03310-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
168 Erklavec Zajec V, Novak U, Kastelic M, Japelj B, Lah L, Pohar A, Likozar B. Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing. Biotechnol Bioeng 2021;118:397-411. [PMID: 32970321 DOI: 10.1002/bit.27578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
169 Tang Y, Cao Y. Modeling the dynamics of antibody-target binding in living tumors. Sci Rep 2020;10:16764. [PMID: 33028895 DOI: 10.1038/s41598-020-73711-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
170 Saleh D, Wang G, Mueller B, Rischawy F, Kluters S, Studts J, Hubbuch J. Cross-scale quality assessment of a mechanistic cation exchange chromatography model. Biotechnol Prog 2021;37:e3081. [PMID: 32926575 DOI: 10.1002/btpr.3081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
171 Biteghe FAN, Mungra N, Chalomie NET, Ndong JC, Engohang-Ndong J, Vignaux G, Padayachee E, Naran K, Barth S. Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies. Oncotarget 2020;11:3531-57. [PMID: 33014289 DOI: 10.18632/oncotarget.27730] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
172 Rajan S, Dall'Acqua WF. Emerging Strategies for Therapeutic Antibody Discovery from Human B Cells. Adv Exp Med Biol 2020;1255:221-30. [PMID: 32949403 DOI: 10.1007/978-981-15-4494-1_18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Wendell SG, Fan H, Zhang C. G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action. Pharmacol Rev 2020;72:1-49. [PMID: 31767622 DOI: 10.1124/pr.118.016899] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
174 Nessa MU, Rahman MA, Kabir Y. Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer. Biomed Res Int 2020;2020:3038564. [PMID: 32908881 DOI: 10.1155/2020/3038564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
175 Wang Y, Gong D, Yao C, Zheng F, Zhou T, Cao Q, Zhu X, Wang M, Zhu J. Human monoclonal anti‑TLR4 antibody negatively regulates lipopolysaccharide‑induced inflammatory responses in mouse macrophages. Mol Med Rep 2020;22:4125-34. [PMID: 32901894 DOI: 10.3892/mmr.2020.11500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
176 Heinhuis KM, Barkman HJ, Beijnen JH, Hendrikx JJMA. A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute. Int J Clin Pharm 2021;43:181-90. [PMID: 32909221 DOI: 10.1007/s11096-020-01131-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
177 Biteghe FAN, Chalomie NET, Mungra N, Vignaux G, Gao N, Vergeade A, Okem A, Naran K, Ndong JC, Barth S. Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma. Biomedicines 2020;8:E327. [PMID: 32899183 DOI: 10.3390/biomedicines8090327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
178 Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol 2021;18:805-28. [PMID: 32879472 DOI: 10.1038/s41423-020-00530-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 48] [Article Influence: 13.3] [Reference Citation Analysis]
179 Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol 2020;11:1986. [PMID: 32983137 DOI: 10.3389/fimmu.2020.01986] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 22.7] [Reference Citation Analysis]
180 Chen X, Shi M, Tong X, Kim HK, Wang LX, Schneewind O, Missiakas D. Glycosylation-dependent opsonophagocytic activity of staphylococcal protein A antibodies. Proc Natl Acad Sci U S A 2020;117:22992-3000. [PMID: 32855300 DOI: 10.1073/pnas.2003621117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
181 Maruthamuthu MK, Rudge SR, Ardekani AM, Ladisch MR, Verma MS. Process Analytical Technologies and Data Analytics for the Manufacture of Monoclonal Antibodies. Trends Biotechnol 2020;38:1169-86. [PMID: 32839030 DOI: 10.1016/j.tibtech.2020.07.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
182 Fernández-Quintero ML, Loeffler JR, Waibl F, Kamenik AS, Hofer F, Liedl KR. Conformational selection of allergen-antibody complexes-surface plasticity of paratopes and epitopes. Protein Eng Des Sel 2019;32:513-23. [PMID: 32719844 DOI: 10.1093/protein/gzaa014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
183 Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1017-24. [PMID: 32762583 DOI: 10.1080/17474124.2020.1807939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
184 Nanna AR, Kel'in AV, Theile C, Pierson JM, Voo ZX, Garg A, Nair JK, Maier MA, Fitzgerald K, Rader C. Generation and validation of structurally defined antibody-siRNA conjugates. Nucleic Acids Res 2020;48:5281-93. [PMID: 32347936 DOI: 10.1093/nar/gkaa286] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
185 Fernández-Quintero ML, Loeffler JR, Bacher LM, Waibl F, Seidler CA, Liedl KR. Local and Global Rigidification Upon Antibody Affinity Maturation. Front Mol Biosci 2020;7:182. [PMID: 32850970 DOI: 10.3389/fmolb.2020.00182] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
186 Van de Velde J, Saller MJ, Eyer K, Voloshin A. Chromatographic clarification overcomes chromatin‐mediated hitch‐hiking interactions on Protein A capture column. Biotechnology and Bioengineering 2020;117:3413-21. [DOI: 10.1002/bit.27513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
187 Grapentin C, Müller C, Kishore RS, Adler M, Elbialy I, Friess W, Huwyler J, Khan TA. Protein-Polydimethylsiloxane Particles in Liquid Vial Monoclonal Antibody Formulations Containing Poloxamer 188. Journal of Pharmaceutical Sciences 2020;109:2393-404. [DOI: 10.1016/j.xphs.2020.03.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
188 Hotinger JA, May AE. Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria. Antibodies (Basel) 2020;9:E35. [PMID: 32726928 DOI: 10.3390/antib9030035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
189 Wells E, Song L, Greer M, Luo Y, Kurian V, Ogunnaike B, Robinson AS. Media supplementation for targeted manipulation of monoclonal antibody galactosylation and fucosylation. Biotechnol Bioeng 2020;117:3310-21. [PMID: 32662879 DOI: 10.1002/bit.27496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
190 Plotkin SS, Cashman NR. Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Neurobiol Dis 2020;144:105010. [PMID: 32682954 DOI: 10.1016/j.nbd.2020.105010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 14.7] [Reference Citation Analysis]
191 Knowling S, Clark J, Sjuts H, Abdiche YN. Direct Comparison of Label-Free Biosensor Binding Kinetics Obtained on the Biacore 8K and the Carterra LSA. SLAS Discov 2020;25:977-84. [PMID: 32646263 DOI: 10.1177/2472555220934814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
192 Wu X, Li Y, Huang B, Ma X, Zhu L, Zheng N, Xu S, Nawaz W, Xu C, Wu Z. A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo. JCI Insight 2020;5:136855. [PMID: 32641581 DOI: 10.1172/jci.insight.136855] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
193 Arslan M, Karadag D, Kalyoncu S. Conformational changes in a Vernier zone region: Implications for antibody dual specificity. Proteins 2020;88:1447-57. [PMID: 32526069 DOI: 10.1002/prot.25964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
194 Gaynor N, Crown J, Collins DM. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Semin Cancer Biol 2020:S1044-579X(20)30152-8. [PMID: 32623044 DOI: 10.1016/j.semcancer.2020.06.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 15.7] [Reference Citation Analysis]
195 Wollacott AM, Xue C, Qin Q, Hua J, Bohnuud T, Viswanathan K, Kolachalama VB. Quantifying the nativeness of antibody sequences using long short-term memory networks. Protein Eng Des Sel 2019;32:347-54. [PMID: 31504835 DOI: 10.1093/protein/gzz031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
196 Garousi J, Orlova A, Frejd FY, Tolmachev V. Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. EJNMMI Radiopharm Chem 2020;5:16. [PMID: 32577943 DOI: 10.1186/s41181-020-00094-w] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
197 Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect 2019;7:e00535. [PMID: 31859459 DOI: 10.1002/prp2.535] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 21.0] [Reference Citation Analysis]
198 Venkataramani S, Ernst R, Derebe MG, Wright R, Kopenhaver J, Jacobs SA, Singh S, Ganesan R. In Pursuit of Stability Enhancement of a Prostate Cancer Targeting Antibody Derived from a Transgenic Animal Platform. Sci Rep 2020;10:9722. [PMID: 32546687 DOI: 10.1038/s41598-020-66636-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
199 Park SG, Choi B, Bae Y, Lee YG, Park SA, Chae YC, Kang S. Selective and Effective Cancer Treatments using Target‐Switchable Intracellular Bacterial Toxin Delivery Systems. Adv Therap 2020;3:2000043. [DOI: 10.1002/adtp.202000043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
200 Andris S, Hubbuch J. Modeling of hydrophobic interaction chromatography for the separation of antibody-drug conjugates and its application towards quality by design. Journal of Biotechnology 2020;317:48-58. [DOI: 10.1016/j.jbiotec.2020.04.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
201 Carillo S, Jakes C, Bones J. In-depth analysis of monoclonal antibodies using microfluidic capillary electrophoresis and native mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2020;185:113218. [DOI: 10.1016/j.jpba.2020.113218] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
202 Raybould MIJ, Marks C, Lewis AP, Shi J, Bujotzek A, Taddese B, Deane CM. Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res 2020;48:D383-8. [PMID: 31555805 DOI: 10.1093/nar/gkz827] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
203 Li C, Yao H, Wang H, Fang J, Xu J. Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.. [DOI: 10.1101/2020.05.26.117770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Mao Y, Kleinberg A, Zhao Y, Raidas S, Li N. Simple Addition of Glycine in Trifluoroacetic Acid-Containing Mobile Phases Enhances the Sensitivity of Electrospray Ionization Mass Spectrometry for Biopharmaceutical Characterization. Anal Chem 2020;92:8691-6. [DOI: 10.1021/acs.analchem.0c01319] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
205 Conner KP, Devanaboyina SC, Thomas VA, Rock DA. The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. Pharmacol Ther 2020;212:107574. [PMID: 32433985 DOI: 10.1016/j.pharmthera.2020.107574] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
206 Marks C, Deane CM. How repertoire data are changing antibody science. J Biol Chem 2020;295:9823-37. [PMID: 32409582 DOI: 10.1074/jbc.REV120.010181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
207 Tang Y, Cao Y. Modeling the dynamics of antibody–target binding in living tumors.. [DOI: 10.1101/2020.05.12.090241] [Reference Citation Analysis]
208 Kini RM. Toxinology provides multidirectional and multidimensional opportunities: A personal perspective. Toxicon X 2020;6:100039. [PMID: 32550594 DOI: 10.1016/j.toxcx.2020.100039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
209 Tang Y, Li X, Cao Y. Quantitatively Modeling Factors that Influence the Therapeutic Doses of Antibodies.. [DOI: 10.1101/2020.05.08.084095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
210 Cheng J, Wang L, Rive CM, Holt RA, Morin GB, Chen DDY. Complementary Methods for de Novo Monoclonal Antibody Sequencing to Achieve Complete Sequence Coverage. J Proteome Res 2020;19:2700-7. [PMID: 32338916 DOI: 10.1021/acs.jproteome.0c00223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
211 Tokunaga Y, Takeuchi K, Okude J, Ori K, Torizawa T, Shimada I. Structural Fingerprints of an Intact Monoclonal Antibody Acquired under Formulated Storage Conditions via 15N Direct Detection Nuclear Magnetic Resonance. J Med Chem 2020;63:5360-6. [PMID: 32374601 DOI: 10.1021/acs.jmedchem.0c00231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
212 Wagner E, Colas O, Chenu S, Goyon A, Murisier A, Cianferani S, François Y, Fekete S, Guillarme D, D’atri V, Beck A. Determination of size variants by CE-SDS for approved therapeutic antibodies: Key implications of subclasses and light chain specificities. Journal of Pharmaceutical and Biomedical Analysis 2020;184:113166. [DOI: 10.1016/j.jpba.2020.113166] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
213 Ebo JS, Saunders JC, Devine PWA, Gordon AM, Warwick AS, Schiffrin B, Chin SE, England E, Button JD, Lloyd C, Bond NJ, Ashcroft AE, Radford SE, Lowe DC, Brockwell DJ. An in vivo platform to select and evolve aggregation-resistant proteins. Nat Commun 2020;11:1816. [PMID: 32286330 DOI: 10.1038/s41467-020-15667-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
214 Nonga OE, Lavogina D, Ivan T, Viht K, Enkvist E, Uri A. Discovery of strong inhibitory properties of a monoclonal antibody of PKA and use of the antibody and a competitive photoluminescent orthosteric probe for analysis of the protein kinase. Biochim Biophys Acta Proteins Proteom 2020;1868:140427. [PMID: 32283249 DOI: 10.1016/j.bbapap.2020.140427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
215 de Wolf ACMT, Herberts CA, Hoefnagel MHN. Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised. Front Med (Lausanne) 2020;7:91. [PMID: 32300597 DOI: 10.3389/fmed.2020.00091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
216 Lee BI, Park MH, Byeon JJ, Shin SH, Choi J, Park Y, Park YH, Chae J, Shin YG. Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody-Drug Conjugate. Molecules 2020;25:E1515. [PMID: 32225092 DOI: 10.3390/molecules25071515] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
217 Xu J, Rehmann MS, Xu M, Zheng S, Hill C, He Q, Borys MC, Li ZJ. Development of an intensified fed-batch production platform with doubled titers using N-1 perfusion seed for cell culture manufacturing. Bioresour Bioprocess 2020;7. [DOI: 10.1186/s40643-020-00304-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
218 Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev 2020;120:3787-851. [PMID: 32202104 DOI: 10.1021/acs.chemrev.9b00738] [Cited by in Crossref: 140] [Cited by in F6Publishing: 152] [Article Influence: 46.7] [Reference Citation Analysis]
219 Ambrosetti F, Olsen TH, Olimpieri PP, Jiménez-garcía B, Milanetti E, Marcatilli P, Bonvin A. proABC-2: PRediction Of AntiBody Contacts v2 and its application to information-driven docking.. [DOI: 10.1101/2020.03.18.967828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
220 Cavdarli S, Delannoy P, Groux-Degroote S. O-acetylated Gangliosides as Targets for Cancer Immunotherapy. Cells 2020;9:E741. [PMID: 32192217 DOI: 10.3390/cells9030741] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
221 Namisaki H, Saito S, Hiraishi K, Haba T, Tanaka Y, Yoshida H, Iida S, Takahashi N. R409K mutation prevents acid-induced aggregation of human IgG4. PLoS One 2020;15:e0229027. [PMID: 32182240 DOI: 10.1371/journal.pone.0229027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
222 Yoo DK, Lee SR, Jung Y, Han H, Lee HK, Han J, Kim S, Chae J, Ryu T, Chung J. Machine Learning-Guided Prediction of Antigen-Reactive In Silico Clonotypes Based on Changes in Clonal Abundance through Bio-Panning. Biomolecules 2020;10:E421. [PMID: 32182714 DOI: 10.3390/biom10030421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
223 Saito S, Namisaki H, Hiraishi K, Takahashi N, Iida S. Engineering a human IgG2 antibody stable at low pH. Protein Sci 2020;29:1186-95. [PMID: 32142185 DOI: 10.1002/pro.3852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
224 Brown ME, Bedinger D, Lilov A, Rathanaswami P, Vásquez M, Durand S, Wallace-Moyer I, Zhong L, Nett JH, Burnina I, Caffry I, Lynaugh H, Sinclair M, Sun T, Bukowski J, Xu Y, Abdiche YN. Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors. PLoS One 2020;15:e0229206. [PMID: 32134960 DOI: 10.1371/journal.pone.0229206] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
225 Heo K, Lee S. TSPAN8 as a Novel Emerging Therapeutic Target in Cancer for Monoclonal Antibody Therapy. Biomolecules 2020;10:E388. [PMID: 32138170 DOI: 10.3390/biom10030388] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
226 Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood 2019;134:1783-6. [PMID: 31537529 DOI: 10.1182/blood.2019002289] [Cited by in Crossref: 71] [Cited by in F6Publishing: 79] [Article Influence: 23.7] [Reference Citation Analysis]
227 Rudge SR, Ladisch MR. Industrial Challenges of Recombinant Proteins. Adv Biochem Eng Biotechnol 2020;171:1-22. [PMID: 31848634 DOI: 10.1007/10_2019_120] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
228 Reader RH, Workman RG, Maddison BC, Gough KC. Advances in the Production and Batch Reformatting of Phage Antibody Libraries. Mol Biotechnol 2019;61:801-15. [PMID: 31468301 DOI: 10.1007/s12033-019-00207-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
229 Tezera LB, Bielecka MK, Ogongo P, Walker NF, Ellis M, Garay-Baquero DJ, Thomas K, Reichmann MT, Johnston DA, Wilkinson KA, Ahmed M, Jogai S, Jayasinghe SN, Wilkinson RJ, Mansour S, Thomas GJ, Ottensmeier CH, Leslie A, Elkington PT. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. Elife 2020;9:e52668. [PMID: 32091388 DOI: 10.7554/eLife.52668] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 15.7] [Reference Citation Analysis]
230 Pepe F, Balatti V. Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. J Clin Med 2020;9:E593. [PMID: 32098192 DOI: 10.3390/jcm9020593] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
231 Corneli P, Conforti C, Retrosi C, Vezzoni R, Meo N, Piccolo V, Farinazzo E, Russo T, Magaton Rizzi G, Giuffrida R, Zalaudek I. Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.13250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
232 Díaz L, Soler D, Tresadern G, Buyck C, Perez-Benito L, Saen-Oon S, Guallar V, Soliva R. Monte Carlo simulations using PELE to identify a protein-protein inhibitor binding site and pose. RSC Adv 2020;10:7058-64. [PMID: 35493910 DOI: 10.1039/d0ra01127d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
233 Mohtar MA, Syafruddin SE, Nasir SN, Low TY. Revisiting the Roles of Pro-Metastatic EpCAM in Cancer. Biomolecules 2020;10. [PMID: 32046162 DOI: 10.3390/biom10020255] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
234 Vainshtein I, Sun B, Roskos LK, Liang M. A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains. Journal of Immunological Methods 2020;477:112688. [DOI: 10.1016/j.jim.2019.112688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
235 Zhang B, Song Y, Fu Y, Zhu B, Wang B, Wang J. Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China. BMC Cancer 2020;20:86. [PMID: 32005140 DOI: 10.1186/s12885-020-6583-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
236 Rocco D, Malapelle U, Del Re M, Della Gravara L, Pepe F, Danesi R, Troncone G, Gridelli C. Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. Expert Opin Drug Metab Toxicol 2020;16:87-96. [PMID: 31978315 DOI: 10.1080/17425255.2020.1721460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
237 Hooft van Huijsduijnen R, Kojima S, Carter D, Okabe H, Sato A, Akahata W, Wells TNC, Katsuno K. Reassessing therapeutic antibodies for neglected and tropical diseases. PLoS Negl Trop Dis 2020;14:e0007860. [PMID: 31999695 DOI: 10.1371/journal.pntd.0007860] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
238 Ching KH, Berg K, Morales J, Pedersen D, Harriman WD, Abdiche YN, Leighton PA. Expression of human lambda expands the repertoire of OmniChickens. PLoS One 2020;15:e0228164. [PMID: 31995598 DOI: 10.1371/journal.pone.0228164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
239 Allen SJ, Lumb KJ. Protein-protein interactions: a structural view of inhibition strategies and the IL-23/IL-17 axis. Adv Protein Chem Struct Biol 2020;121:253-303. [PMID: 32312425 DOI: 10.1016/bs.apcsb.2019.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
240 Sellmann C, Pekar L, Bauer C, Ciesielski E, Krah S, Becker S, Toleikis L, Kügler J, Frenzel A, Valldorf B, Hust M, Zielonka S. A One-Step Process for the Construction of Phage Display scFv and VHH Libraries. Mol Biotechnol 2020;62:228-39. [DOI: 10.1007/s12033-020-00236-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
241 Meyer DW, Bou LB, Shum S, Jonas M, Anderson ME, Hamilton JZ, Hunter JH, Wo SW, Wong AO, Okeley NM, Lyon RP. An in Vitro Assay Using Cultured Kupffer Cells Can Predict the Impact of Drug Conjugation on in Vivo Antibody Pharmacokinetics. Mol Pharmaceutics 2020;17:802-9. [DOI: 10.1021/acs.molpharmaceut.9b00991] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
242 Milazzo FM, Vesci L, Anastasi AM, Chiapparino C, Rosi A, Giannini G, Taddei M, Cini E, Faltoni V, Petricci E, Battistuzzi G, Salvini L, Carollo V, De Santis R. ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1. Front Oncol 2019;9:1534. [PMID: 32039017 DOI: 10.3389/fonc.2019.01534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
243 Farràs M, Román R, Camps M, Miret J, Martínez Ó, Pujol X, Casablancas A, Cairó JJ. Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab. BMC Mol Cell Biol 2020;21:2. [PMID: 31964343 DOI: 10.1186/s12860-019-0244-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
244 Arias-Pinilla GA, Dalgleish AG, Mudan S, Bagwan I, Walker AJ, Modjtahedi H. Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer. Sci Rep 2020;10:537. [PMID: 31953437 DOI: 10.1038/s41598-019-57287-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
245 Cavaco M, Gaspar D, Arb Castanho M, Neves V. Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Pharmaceutics 2020;12:E62. [PMID: 31940974 DOI: 10.3390/pharmaceutics12010062] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
246 Upadhyaya C, Jiao X, Ashton A, Patel K, Kossenkov AV, Pestell RG. The G protein coupled receptor CCR5 in cancer. Adv Cancer Res 2020;145:29-47. [PMID: 32089164 DOI: 10.1016/bs.acr.2019.11.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
247 Davidson HW, Zhang L. Immune therapies for autoimmune diabetes targeting pathogenic peptide-MHC complexes. J Mol Cell Biol 2020;12:759-63. [PMID: 32663282 DOI: 10.1093/jmcb/mjaa037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
248 Zhou J, Gao H, Xie W, Li Y. Bovine serum albumin affects N-glycoforms of murine IgG monoclonal antibody purified from hybridoma supernatants. Appl Microbiol Biotechnol 2020;104:1583-94. [PMID: 31915902 DOI: 10.1007/s00253-019-10309-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
249 Leung D, Wurst JM, Liu T, Martinez RM, Datta-Mannan A, Feng Y. Antibody Conjugates-Recent Advances and Future Innovations. Antibodies (Basel) 2020;9:E2. [PMID: 31936270 DOI: 10.3390/antib9010002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 16.3] [Reference Citation Analysis]
250 Reichert JM. [Antibody therapeutics: an American view of an amazing present and future]. Med Sci (Paris) 2019;35:924-5. [PMID: 31903895 DOI: 10.1051/medsci/2019244] [Reference Citation Analysis]
251 Ketterer B, Moore-Kelly C, Thomas ORT, Franzreb M. Integrated system for temperature-controlled fast protein liquid chromatography. III. Continuous downstream processing of monoclonal antibodies. J Chromatogr A 2020;1609:460429. [PMID: 31431354 DOI: 10.1016/j.chroma.2019.460429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
252 Anees P, Gauthier MA. Homogenous Scavenging Resolves Low-Purification Yield/Selectivity Caused by Secondary Binding of Protein-A to Antigen-Binding Antibody Fragments. Biomacromolecules 2020;21:825-9. [PMID: 31841628 DOI: 10.1021/acs.biomac.9b01516] [Reference Citation Analysis]
253 Masuda Y, Ogino Y, Yamaichi K, Takahashi Y, Nonaka K, Wakamatsu K. The prevention of an anomalous chromatographic behavior and the resulting successful removal of viruses from monoclonal antibody with an asymmetric charge distribution by using a membrane adsorber in highly efficient, anion-exchange chromatography in flow-through mode. Biotechnol Prog 2020;36:e2955. [PMID: 31894893 DOI: 10.1002/btpr.2955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
254 Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 2020;27:1. [PMID: 31894001 DOI: 10.1186/s12929-019-0592-z] [Cited by in Crossref: 698] [Cited by in F6Publishing: 728] [Article Influence: 232.7] [Reference Citation Analysis]
255 Kavara A, Sokolowski D, Collins M, Schofield M. Recent advances in continuous downstream processing of antibodies and related products. Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics 2020. [DOI: 10.1016/b978-0-08-103019-6.00004-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
256 Georges GJ, Dengl S, Bujotzek A, Hesse F, Fischer JA, Gärtner A, Benz J, Lauer ME, Ringler P, Stahlberg H, Plath F, Brinkmann U, Imhof-jung S. The Contorsbody, an antibody format for agonism: Design, structure, and function. Computational and Structural Biotechnology Journal 2020;18:1210-20. [DOI: 10.1016/j.csbj.2020.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
257 Robotham AC, Kelly JF. LC-MS characterization of antibody-based therapeutics. Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics 2020. [DOI: 10.1016/b978-0-08-103019-6.00001-1] [Reference Citation Analysis]
258 Megahed MA, El-sawy HS, El-say KM. The promising expedition of the delivery systems for monoclonal antibodies. Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents 2020. [DOI: 10.1016/b978-0-12-819666-3.00003-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
259 Yue L, Yan Z, Li H, Liu X, Sun P. Brij-58, a potential injectable protein-stabilizer used in therapeutic protein formulation. European Journal of Pharmaceutics and Biopharmaceutics 2020;146:73-83. [DOI: 10.1016/j.ejpb.2019.12.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
260 Chahar DS, Ravindran S, Pisal S. Monoclonal antibody purification and its progression to commercial scale. Biologicals 2020;63:1-13. [DOI: 10.1016/j.biologicals.2019.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
261 Leung WW. Introduction. Centrifugal Separations in Biotechnology 2020. [DOI: 10.1016/b978-0-08-102634-2.00001-5] [Reference Citation Analysis]
262 Kang H, Larson NR, White DR, Middaugh CR, Tolbert T, Schöneich C. Effects of Glycan Structure on the Stability and Receptor Binding of an IgG4-Fc. Journal of Pharmaceutical Sciences 2020;109:677-89. [DOI: 10.1016/j.xphs.2019.10.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
263 Soliman C, Pier GB, Ramsland PA. Antibody recognition of bacterial surfaces and extracellular polysaccharides. Curr Opin Struct Biol 2020;62:48-55. [PMID: 31874385 DOI: 10.1016/j.sbi.2019.12.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
264 Soond SM, Zamyatnin AA Jr. Targeting G protein-coupled receptors in cancer therapy. Adv Cancer Res 2020;145:49-97. [PMID: 32089165 DOI: 10.1016/bs.acr.2019.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
265 Morishita R, Sugiyama S, Denda M, Tokunaga S, Kido K, Shioya R, Ozawa S, Sawasaki T. CF-PA2Vtech: a cell-free human protein array technology for antibody validation against human proteins. Sci Rep 2019;9:19349. [PMID: 31852950 DOI: 10.1038/s41598-019-55785-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
266 Steinhardt J, Wu Y, Fleming R, Ruddle BT, Patel P, Wu H, Gao C, Dimasi N. Fab-Arm Exchange Combined with Selective Protein A Purification Results in a Platform for Rapid Preparation of Monovalent Bispecific Antibodies Directly from Culture Media. Pharmaceutics 2019;12:E3. [PMID: 31861347 DOI: 10.3390/pharmaceutics12010003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
267 Gaston J, Maestrali N, Lalle G, Gagnaire M, Masiero A, Dumas B, Dabdoubi T, Radošević K, Berne PF. Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions. Sci Rep 2019;9:18688. [PMID: 31822703 DOI: 10.1038/s41598-019-55091-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
268 de Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability. Antibodies (Basel) 2019;8:E57. [PMID: 31817406 DOI: 10.3390/antib8040057] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 14.5] [Reference Citation Analysis]
269 Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies (Basel) 2019;8:E55. [PMID: 31816964 DOI: 10.3390/antib8040055] [Cited by in Crossref: 129] [Cited by in F6Publishing: 140] [Article Influence: 32.3] [Reference Citation Analysis]
270 Kristoff CJ, Bwanali L, Veltri LM, Gautam GP, Rutto PK, Newton EO, Holland LA. Challenging Bioanalyses with Capillary Electrophoresis. Anal Chem 2020;92:49-66. [PMID: 31698907 DOI: 10.1021/acs.analchem.9b04718] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
271 Emami F, Vatanara A, Vakhshiteh F, Kim Y, Kim TW, Na DH. Amino acid-based stable adalimumab formulation in spray freeze-dried microparticles for pulmonary delivery. Journal of Drug Delivery Science and Technology 2019;54:101249. [DOI: 10.1016/j.jddst.2019.101249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
272 Brämer C, Tünnermann L, Gonzalez Salcedo A, Reif OW, Solle D, Scheper T, Beutel S. Membrane Adsorber for the Fast Purification of a Monoclonal Antibody Using Protein A Chromatography. Membranes (Basel) 2019;9:E159. [PMID: 31783640 DOI: 10.3390/membranes9120159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
273 Huen J, Yan Z, Iwashkiw J, Dubey S, Gimenez MC, Ortiz ME, Patel SV, Jones MD, Riazi A, Terebiznik M, Babaei S, Shahinas D. A Novel Single Domain Antibody Targeting FliC Flagellin of Salmonella enterica for Effective Inhibition of Host Cell Invasion. Front Microbiol 2019;10:2665. [PMID: 31849856 DOI: 10.3389/fmicb.2019.02665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
274 Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, Krenz B, Lutz J, Rasche L, Hönemann D, Neuweiler H, Heiby JC, Bargou RC, Wajant H, Einsele H, Riethmüller G, Stuhler G. On-target restoration of a split T cell-engaging antibody for precision immunotherapy. Nat Commun 2019;10:5387. [PMID: 31772172 DOI: 10.1038/s41467-019-13196-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
275 Sjuts H, Schreuder H, Engel CK, Bussemer T, Gokarn Y. Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs. Drug Dev Res 2020;81:329-37. [PMID: 31758731 DOI: 10.1002/ddr.21624] [Reference Citation Analysis]
276 Goulet DR, Zwolak A, Williams JA, Chiu ML, Atkins WM. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors. Proteins 2020;88:689-97. [PMID: 31702857 DOI: 10.1002/prot.25853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
277 Kranjc MK, Novak M, Pestell RG, Lah TT. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme. Radiol Oncol 2019;53:397-406. [PMID: 31747383 DOI: 10.2478/raon-2019-0057] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
278 Karadag M, Arslan M, Kaleli NE, Kalyoncu S. Physicochemical determinants of antibody-protein interactions. Adv Protein Chem Struct Biol 2020;121:85-114. [PMID: 32312427 DOI: 10.1016/bs.apcsb.2019.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
279 Lin X, Lu X, Luo G, Xiang H. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. Eur J Med Chem 2020;186:111876. [PMID: 31761384 DOI: 10.1016/j.ejmech.2019.111876] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 13.3] [Reference Citation Analysis]
280 Ambrosetti F, Jiménez-García B, Roel-Touris J, Bonvin AMJJ. Modeling Antibody-Antigen Complexes by Information-Driven Docking. Structure 2020;28:119-129.e2. [PMID: 31727476 DOI: 10.1016/j.str.2019.10.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
281 Wang W, Hao D, Ge J, Zhao L, Huang Y, Zhu K, Wu X, Su Z, Yu R, Ma G. A minimalist peptide ligand for IgG by minimizing the binding domain of protein A. Biochemical Engineering Journal 2019;151:107327. [DOI: 10.1016/j.bej.2019.107327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
282 Du C, Xu J, Song H, Tao L, Lewandowski A, Ghose S, Borys MC, Li ZJ. Mechanisms of color formation in drug substance and mitigation strategies for the manufacture and storage of therapeutic proteins produced using mammalian cell culture. Process Biochemistry 2019;86:127-35. [DOI: 10.1016/j.procbio.2019.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
283 Serrano L, Maloney V, Gordon KB. Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy 2019;11:1357-70. [DOI: 10.2217/imt-2019-0116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
284 Ch'ng ACW, Konthur Z, Lim TS. Magnetic bead-based semi-automated phage display panning strategy for the directed evolution of antibodies. Methods Enzymol 2020;630:159-78. [PMID: 31931984 DOI: 10.1016/bs.mie.2019.10.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
285 Akiba H, Tamura H, Kiyoshi M, Yanaka S, Sugase K, Caaveiro JMM, Tsumoto K. Structural and thermodynamic basis for the recognition of the substrate-binding cleft on hen egg lysozyme by a single-domain antibody. Sci Rep 2019;9:15481. [PMID: 31664051 DOI: 10.1038/s41598-019-50722-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
286 Wu MA. Lanadelumab for the treatment of hereditary angioedema. Expert Opin Biol Ther 2019;19:1233-45. [PMID: 31657963 DOI: 10.1080/14712598.2019.1685490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
287 Melani RD, Srzentić K, Gerbasi VR, McGee JP, Huguet R, Fornelli L, Kelleher NL. Direct measurement of light and heavy antibody chains using ion mobility and middle-down mass spectrometry. MAbs 2019;11:1351-7. [PMID: 31607219 DOI: 10.1080/19420862.2019.1668226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
288 Sarmento-Ribeiro AB, Scorilas A, Gonçalves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resist Updat 2019;47:100646. [PMID: 31733611 DOI: 10.1016/j.drup.2019.100646] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 13.8] [Reference Citation Analysis]
289 Bobrowicz M, Zagozdzon R, Domagala J, Vasconcelos-Berg R, Guenova E, Winiarska M. Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives. Cancers (Basel) 2019;11:E1420. [PMID: 31554169 DOI: 10.3390/cancers11101420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
290 Scheffel J, Kanje S, Borin J, Hober S. Optimization of a calcium-dependent Protein A-derived domain for mild antibody purification. MAbs 2019;11:1492-501. [PMID: 31526164 DOI: 10.1080/19420862.2019.1662690] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
291 Fekete S, Beck A, Veuthey J, Guillarme D. Proof of Concept To Achieve Infinite Selectivity for the Chromatographic Separation of Therapeutic Proteins. Anal Chem 2019;91:12954-61. [DOI: 10.1021/acs.analchem.9b03005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
292 Ruane S, Li Z, Campana M, Hu X, Gong H, Webster JRP, Uddin F, Kalonia C, Bishop SM, van der Walle CF, Lu JR. Interfacial Adsorption of a Monoclonal Antibody and Its Fab and Fc Fragments at the Oil/Water Interface. Langmuir 2019;35:13543-52. [DOI: 10.1021/acs.langmuir.9b02317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
293 Zhou Z, Austin GL, Shaffer R, Armstrong DD, Gentry MS. Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases. Trends Mol Med 2019;25:1094-109. [PMID: 31522955 DOI: 10.1016/j.molmed.2019.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
294 Gu C, Yang J. Risankizumab for the treatment of psoriasis. Expert Rev Clin Pharmacol 2019;12:851-7. [PMID: 31460804 DOI: 10.1080/17512433.2019.1657829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
295 Petitcollin A, Bensalem A, Verdier M, Tron C, Lemaitre F, Paintaud G, Bellissant E, Ternant D. Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review. Clin Pharmacokinet 2020;59:37-49. [DOI: 10.1007/s40262-019-00816-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
296 Griffiths K, Binder U, McDowell W, Tommasi R, Frigerio M, Darby WG, Hosking CG, Renaud L, Machacek M, Lloyd P, Skerra A, Foley M. Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. MAbs 2019;11:1331-40. [PMID: 31156041 DOI: 10.1080/19420862.2019.1626652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
297 Qi J, Hymel D, Nelson CG, Burke TR Jr, Rader C. Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. Front Immunol 2019;10:1994. [PMID: 31497024 DOI: 10.3389/fimmu.2019.01994] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
298 Qi H, Ma M, Hu C, Xu Z, Wu F, Wang N, Lai D, Li Y, Guo S, Zhao X, Li H, Tao S. Antibody binding epitope Mapping (AbMap) of two hundred antibodies in a single run.. [DOI: 10.1101/739342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
299 Alfano G, Cappelli G, Fontana F, Di Lullo L, Di Iorio B, Bellasi A, Guaraldi G. Kidney Disease in HIV Infection. J Clin Med 2019;8:E1254. [PMID: 31430930 DOI: 10.3390/jcm8081254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
300 Hu T, Buus TB, Krejsgaard T, Nansen A, Lundholt BK, Spee P, Fredholm S, Petersen DL, Blümel E, Gluud M, Monteiro MN, Willerslev-Olsen A, Andersen MH, Straten PT, Met Ö, Stolearenco V, Fogh H, Gniadecki R, Nastasi C, Litman T, Woetmann A, Gjerdrum LMR, Ødum N. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome. Oncotarget 2019;10:4894-906. [PMID: 31448055 DOI: 10.18632/oncotarget.27122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
301 Giannini G, Milazzo FM, Battistuzzi G, Rosi A, Anastasi AM, Petronzelli F, Albertoni C, Tei L, Leone L, Salvini L, De Santis R. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorganic & Medicinal Chemistry 2019;27:3248-53. [DOI: 10.1016/j.bmc.2019.05.047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
302 Lecerf M, Kanyavuz A, Lacroix-desmazes S, Dimitrov JD. Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies. Molecular Immunology 2019;112:338-46. [DOI: 10.1016/j.molimm.2019.06.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
303 Chau CH, Steeg PS, Figg WD. Antibody–drug conjugates for cancer. The Lancet 2019;394:793-804. [DOI: 10.1016/s0140-6736(19)31774-x] [Cited by in Crossref: 235] [Cited by in F6Publishing: 253] [Article Influence: 58.8] [Reference Citation Analysis]
304 Murisier A, Farsang E, Horváth K, Lauber M, Beck A, Guillarme D, Fekete S. Tuning selectivity in cation-exchange chromatography applied for monoclonal antibody separations, part 2: Evaluation of recent stationary phases. Journal of Pharmaceutical and Biomedical Analysis 2019;172:320-8. [DOI: 10.1016/j.jpba.2019.05.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
305 Laustsen AH. How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases? Expert Opin Drug Discov 2019;14:1103-12. [PMID: 31364421 DOI: 10.1080/17460441.2019.1646723] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
306 Stavenhagen K, Gahoual R, Dominguez Vega E, Palmese A, Ederveen ALH, Cutillo F, Palinsky W, Bierau H, Wuhrer M. Site-specific N- and O-glycosylation analysis of atacicept. MAbs 2019;11:1053-63. [PMID: 31349756 DOI: 10.1080/19420862.2019.1630218] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
307 Merkul E, Sijbrandi NJ, Muns JA, Aydin I, Adamzek K, Houthoff HJ, Nijmeijer B, Van Dongen GAMS. First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs). Expert Opin Drug Deliv 2019;16:783-93. [PMID: 31327255 DOI: 10.1080/17425247.2019.1645118] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
308 Zhang Y, Fang C, Wang RE, Wang Y, Guo H, Guo C, Zhao L, Li S, Li X, Schultz PG, Cao YJ, Wang F. A tumor-targeted immune checkpoint blocker. Proc Natl Acad Sci U S A 2019;116:15889-94. [PMID: 31332018 DOI: 10.1073/pnas.1905646116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
309 Del Solar V, Contel M. Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer. J Inorg Biochem 2019;199:110780. [PMID: 31434020 DOI: 10.1016/j.jinorgbio.2019.110780] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
310 Raybould MIJ, Marks C, Lewis AP, Shi J, Bujotzek A, Taddese B, Deane CM. Thera-SAbDab: the Therapeutic Structural Antibody Database.. [DOI: 10.1101/707521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
311 Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity. 2019;52:144-160. [PMID: 31298041 DOI: 10.1080/08916934.2019.1641200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
312 Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology. Cancer Res 2019;79:4801-7. [PMID: 31292161 DOI: 10.1158/0008-5472.CAN-19-1167] [Cited by in Crossref: 98] [Cited by in F6Publishing: 103] [Article Influence: 24.5] [Reference Citation Analysis]
313 Pucca MB, Cerni FA, Janke R, Bermúdez-Méndez E, Ledsgaard L, Barbosa JE, Laustsen AH. History of Envenoming Therapy and Current Perspectives. Front Immunol 2019;10:1598. [PMID: 31354735 DOI: 10.3389/fimmu.2019.01598] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
314 Melani RD, Srzentić K, Gerbasi VR, Mcgee JP, Huguet R, Fornelli L, Kelleher NL. Direct Measurement of Light and Heavy Antibody Chains Using Differential Ion Mobility Spectrometry and Middle-Down Mass Spectrometry.. [DOI: 10.1101/693473] [Reference Citation Analysis]
315 Kon E, Benhar I. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resistance Updates 2019;45:13-29. [DOI: 10.1016/j.drup.2019.07.004] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
316 Lionetto L, Curto M, Cisale GY, Capi M, Cipolla F, Guglielmetti M, Martelletti P. Fremanezumab for the preventive treatment of migraine in adults. Expert Rev Clin Pharmacol 2019;12:741-8. [PMID: 31220963 DOI: 10.1080/17512433.2019.1635452] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
317 Tabasinezhad M, Talebkhan Y, Wenzel W, Rahimi H, Omidinia E, Mahboudi F. Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches. Immunol Lett 2019;212:106-13. [PMID: 31247224 DOI: 10.1016/j.imlet.2019.06.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
318 Alpaugh M, Cicchetti F. A brief history of antibody-based therapy. Neurobiol Dis 2019;130:104504. [PMID: 31216439 DOI: 10.1016/j.nbd.2019.104504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
319 Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol 2019;10:1296. [PMID: 31231397 DOI: 10.3389/fimmu.2019.01296] [Cited by in Crossref: 148] [Cited by in F6Publishing: 158] [Article Influence: 37.0] [Reference Citation Analysis]
320 Bygum A. Hereditary Angio-Oedema for Dermatologists. Dermatology 2019;235:263-75. [PMID: 31167185 DOI: 10.1159/000500196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
321 Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci 2020;109:74-103. [PMID: 31173761 DOI: 10.1016/j.xphs.2019.05.031] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 19.0] [Reference Citation Analysis]
322 Vásquez M, Krauland E, Walker L, Wittrup D, Gerngross T. Connecting the sequence dots: shedding light on the genesis of antibodies reported to be designed in silico. MAbs 2019;11:803-8. [PMID: 31107637 DOI: 10.1080/19420862.2019.1611172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
323 Bivi N, Moore T, Rodgers G, Denning H, Shockley T, Swearingen CA, Gelfanova V, Calderon B, Peterson DA, Hodsdon ME, Siegel RW, Higgs RE, Konrad RJ. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk. MAbs 2019;11:861-9. [PMID: 31099718 DOI: 10.1080/19420862.2019.1612699] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
324 Béné MC. The wonderful story of monoclonal antibodies. Int J Lab Hematol 2019;41 Suppl 1:8-14. [PMID: 31069973 DOI: 10.1111/ijlh.13006] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
325 Mao Y, Zhang L, Kleinberg A, Xia Q, Daly TJ, Li N. Fast protein sequencing of monoclonal antibody by real-time digestion on emitter during nanoelectrospray. MAbs 2019;11:767-78. [PMID: 30919719 DOI: 10.1080/19420862.2019.1599633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
326 Sokullu E, Soleymani Abyaneh H, Gauthier MA. Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics. Pharmaceutics 2019;11:E211. [PMID: 31058814 DOI: 10.3390/pharmaceutics11050211] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
327 Datta-Mannan A. Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides. Drug Metab Dispos 2019;47:1100-10. [PMID: 31043438 DOI: 10.1124/dmd.119.086488] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
328 Arena TA, Chou B, Harms PD, Wong AW. An anti-apoptotic HEK293 cell line provides a robust and high titer platform for transient protein expression in bioreactors. MAbs 2019;11:977-86. [PMID: 30907238 DOI: 10.1080/19420862.2019.1598230] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
329 Du Q, Damschroder M, Pabst TM, Hunter AK, Wang WK, Luo H. Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions. MAbs 2019;11:789-802. [PMID: 30913985 DOI: 10.1080/19420862.2019.1599634] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
330 Kaleli NE, Karadag M, Kalyoncu S. Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues. Proteins 2019;87:607-18. [DOI: 10.1002/prot.25685] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
331 Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med 2019;25:547-53. [PMID: 30936546 DOI: 10.1038/s41591-019-0412-8] [Cited by in Crossref: 143] [Cited by in F6Publishing: 144] [Article Influence: 35.8] [Reference Citation Analysis]
332 Barderas R, Benito-Peña E. The 2018 Nobel Prize in Chemistry: phage display of peptides and antibodies.Anal Bioanal Chem. 2019;411:2475-2479. [PMID: 30888467 DOI: 10.1007/s00216-019-01714-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
333 Deng M. The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China. Antib Ther 2019;2:54-5. [PMID: 33928222 DOI: 10.1093/abt/tbz005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
334 Cambay F, Henry O, Durocher Y, De Crescenzo G. Impact of N-glycosylation on Fcγ receptor / IgG interactions: unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions. MAbs 2019;11:435-52. [PMID: 30822189 DOI: 10.1080/19420862.2019.1581017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
335 Beck A, D’atri V, Ehkirch A, Fekete S, Hernandez-alba O, Gahoual R, Leize-wagner E, François Y, Guillarme D, Cianférani S. Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future. Expert Review of Proteomics 2019;16:337-62. [DOI: 10.1080/14789450.2019.1578215] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
336 Limpikirati P, Hale JE, Hazelbaker M, Huang Y, Jia Z, Yazdani M, Graban EM, Vaughan RC, Vachet RW. Covalent labeling and mass spectrometry reveal subtle higher order structural changes for antibody therapeutics. MAbs 2019;11:463-76. [PMID: 30636503 DOI: 10.1080/19420862.2019.1565748] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
337 Brown AJ, Snapkov I, Akbar R, Pavlović M, Miho E, Sandve GK, Greiff V. Augmenting adaptive immunity: progress and challenges in the quantitative engineering and analysis of adaptive immune receptor repertoires. Mol Syst Des Eng 2019;4:701-36. [DOI: 10.1039/c9me00071b] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]